TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery(TM) (PEDD(TM)) via the TriNav® Infusion System

Stock Information for Biote Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Biote Corp.

TriSalus Life Sciences Announces Key Appointments to Board of Directors
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed
TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call
TriSalus Announces Leadership Changes
TriSalus Reports Q3 2024 Financial Results and Provides Business Update
TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer
TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide(TM) Guiding Catheters, Expanding Portfolio of PEDD(TM) Devices for Improved Tumor Treatment
TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.